Capital International Investors Takes $41.07 Million Position in Cellebrite DI Ltd. $CLBT

Capital International Investors bought a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,278,040 shares of the company’s stock, valued at approximately $41,073,000. Capital International Investors owned approximately 0.95% of Cellebrite DI at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of CLBT. Cooper Creek Partners Management LLC bought a new stake in shares of Cellebrite DI during the 3rd quarter valued at about $55,999,000. Granahan Investment Management LLC boosted its stake in shares of Cellebrite DI by 1,108.5% during the 3rd quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock valued at $48,721,000 after purchasing an additional 2,411,726 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Cellebrite DI by 58.6% during the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after purchasing an additional 2,054,644 shares in the last quarter. Pertento Partners LLP boosted its stake in Cellebrite DI by 57.8% during the third quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock worth $86,131,000 after acquiring an additional 1,702,574 shares in the last quarter. Finally, Portolan Capital Management LLC boosted its stake in Cellebrite DI by 139.1% during the third quarter. Portolan Capital Management LLC now owns 2,419,662 shares of the company’s stock worth $44,836,000 after acquiring an additional 1,407,818 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock opened at $12.98 on Wednesday. The stock has a market capitalization of $3.24 billion, a PE ratio of 46.36, a price-to-earnings-growth ratio of 1.66 and a beta of 1.17. Cellebrite DI Ltd. has a 52-week low of $11.02 and a 52-week high of $19.98. The company has a 50-day simple moving average of $13.27 and a two-hundred day simple moving average of $15.12.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. DA Davidson assumed coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They set a “buy” rating and a $20.00 price objective on the stock. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Finally, Needham & Company LLC dropped their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Insider Transactions at Cellebrite DI

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 13,269 shares of company stock valued at $169,592 over the last three months. 5.70% of the stock is currently owned by insiders.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.